Poor
Mostly Aligned
Patient Risk:
Low
Summary
Overall alignment is poor. The claims include several unsupported statements and omit major label sections (contraindications, boxed warnings, pregnancy/pediatric safety, and dosing safety). Supported claims align with the label for fixed-dose combination, administration with/without food, and hyperuricemia risk; however, many expected safety and usage details are missing or inaccurate relative to the provided label.
Category Scores
Accurate Statements
Nexlizet is a fixed-dose combination of bempedoic acid and ezetimibe.
11
Nexlizet can be taken with or without food.
2.1
Nexlizet may interact with other medications.
7
Bempedoic acid can raise uric acid.
5.1
Raising uric acid with bempedoic acid can lead to gout or painful uric acid flares.
5.1
Unsupported Statements
Nexlizet lowers LDL cholesterol.
Not supported by the provided label sections.
Nexlizet can cause nausea.
Not supported by the provided label sections.
Nexlizet can cause diarrhea.
Not supported by the provided label sections.
Nexlizet can cause back pain.
Not supported by the provided label sections.
Nexlizet can cause joint pain.
Not supported by the provided label sections.
Nexlizet can cause headaches.
Not supported by the provided label sections.
Nexlizet offers convenience due to being a fixed-dose combination (fewer pills).
Not supported by the provided label sections.
Effectiveness and tolerability of Nexlizet vary among individuals.
Not supported by the provided label sections.
Monitoring labs is advised during Nexlizet therapy.
Not supported by the provided label sections.
Monitoring liver enzymes is advised during Nexlizet therapy.
Not supported by the provided label sections.
Contradictions
Important Omissions
Contraindications, boxed warnings, dosing safety/dose adjustments, pregnancy risk, and pediatric safety information are not addressed by the claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Includes hyperuricemia risk and gout signal as per label; no additional risk beyond label claims is introduced.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Major omissions: contraindications, boxed warnings, dosing safety, pregnancy, and pediatric safety information not addressed.
Suggested Improvement
Incorporate all core label sections (contraindications, boxed warnings, detailed dosing safety and dose adjustments, pregnancy/pediatric safety) and verify adverse reactions and administration details against the label.